The company creates therapy based on virtual reality and gamification, merging neuroscientific insights with therapeutic techniques. VRtech Düsseldorf medtech business CUREOSITY has raised an additional €3.8 million, bringing the total capital to more than €8.4 million.

The company creates therapy based on virtual reality and gamification, combining neuroscientific discoveries, particularly the potential of neuroplasticity, with extensive therapy expertise.
The 50  trainings in 7 modules are applicable to physiotherapy, occupational therapy, and neuropsychology in all phases and locations. They target individuals with sensorimotor, cognitive, and perceptual deficits.

Since the market debut of the VR therapy CUREO®, the SaaS company has developed significantly and is currently used in around 200 therapeutic facilities in 24 countries. Caesar van Heyningen, CEO, stated that the CUREO® therapeutic software was inspired by the creators’ personal needs. The finance will support the company’s growth and high-quality upgrades to the program.

We intend to spend extensively in commercial expansion, including future technical possibilities into our product roadmap today. With this fundraising round, we can assure financial independence and long-term business operations. A privilege, especially under these tight market conditions.”

Investors include the TechVision Fund (TVF) and the Belgian family office Nomainvest. According to Björn Lang, Partner at TVF, CUREOSITY addresses the shortage of competent people in the field of therapy. Smart solutions like CUREO® are more relevant to society, particularly in light of demographic changes. The increased financing will support CUREO®’s market leadership in VR therapy.

Read More: Click Here